ProPhase Labs Files Q1 2025 10-Q

Ticker: PRPH · Form: 10-Q · Filed: May 20, 2025 · CIK: 868278

Prophase Labs, INC. 10-Q Filing Summary
FieldDetail
CompanyProphase Labs, INC. (PRPH)
Form Type10-Q
Filed DateMay 20, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, quarterly-report, pharmaceuticals

TL;DR

ProPhase Labs Q1 2025 10-Q filed. Financials look steady.

AI Summary

ProPhase Labs, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial figures and business segment information are presented, reflecting the company's ongoing activities in the pharmaceutical preparations sector.

Why It Matters

This filing provides investors and analysts with the latest financial health and operational status of ProPhase Labs, Inc. for the first quarter of 2025.

Risk Assessment

Risk Level: low — The filing is a standard quarterly report with no immediate red flags or significant negative disclosures.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of ProPhase Labs, Inc.?

ProPhase Labs, Inc. is primarily involved in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].

What is the fiscal year end for ProPhase Labs, Inc.?

The fiscal year end for ProPhase Labs, Inc. is December 31 (1231).

What is the company's former name and when was it changed?

The company's former name was QUIGLEY CORP, and the name change occurred on March 28, 1993 (19930328).

What is the SEC file number for ProPhase Labs, Inc.?

The SEC file number for ProPhase Labs, Inc. is 000-21617.

What is the business address of ProPhase Labs, Inc.?

The business address is 711 STEWART AVE, SUITE 200, GARDEN CITY, NEW YORK, NY 11530.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 20, 2025 regarding ProPhase Labs, Inc. (PRPH).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing